

Guidelines for Pain Management in Acute and Chronic Pain: Focus on Opiates

Jeffrey Fudin, Pharm.D. DAAPM
Clinical Pharmacy Specialist-Pain Management
Dept. of Veterans Affairs Medical Center-Albany, NY
Associate Professor of Pharmacy Practice, Albany College of Pharmacy

*Please visit American Pharmaceutical
Care Pain Consultants at
www.paindr.com*

06-26-2005 PSSNY


LEARNING OBJECTIVES:

Upon completion of this overview, the attendee should be able to:

1. Understand the concept of BALANCE among clinicians who prescribe opioid pain medications, clinicians who treat addiction, dispensing pharmacists, those who regulate, and those who enforce legislation.
2. Discuss the safe and appropriate use of long acting opioid analgesics as well as comparing delivery systems and emerging therapies in chronic pain management for improved quality of life.
3. Compare and Contrast Addiction, Pseudo-addiction, Tolerance, Physical Dependence, and discuss relative risks factors of aberrant behavior.
4. Understand the role and necessary content of an opioid agreement, and how a tri-lateral agreement (patient, prescriber, pharmacist) can effectively be utilized.
5. List the appropriate proactive and reactive dispensing/prescribing/monitoring strategies based on perceived patient risk.
6. Understand the medicinal chemistry of opioids and apply this knowledge to drug selection and aiding prescribers to accurately perform and interpret, urine and serum opioid monitoring.


Chemical Classes of Opioids

PHENANTHRENES




MORPHINE

BENZOMORPHANS




PENTAZOCINE

PHENYLPYPERIDINES



MEPERIDINE

DIPHENYLHEPTANES



METHADONE

Rx EXAMPLES >

morphine
codeine
hydrocodone*
hydromorphone*
levorphanol*
oxycodone*
oxymorphone*
buprenorphine*
nalbuphine
butorphanol*
naloxone*
heroin (diacetyl-morphine)

pentazocine
diphenoxylate
loperamide

meperidine
fentanyl
sufentanil
alfentanil
remifentanil

methadone
propoxyphene

X-SENSATIVITY >

PROBABLE

POSSIBLE

LOW RISK

LOW RISK

*These agents lack the 6-OH group of morphine, possibly decreasing cross-sensitivity within the phenanthrene group.

Courtesy of Dr. Jeffrey Fudin

References:

Reisine T, Pasternak G. Opioid analgesics and antagonists. In Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill Companies; 1996:521-555.

Willette RE. Analgesic Agents. In: Wilson and Grisvold's Textbook of Organic Medicinal Chemistry. Ninth Edition, Editors: Delgado JN, Remers WA. JB Lippincott Company, Philadelphia, PA. 1991:629-654.

References:

Baselt RC, Cravey RH. Disposition of toxic drugs and chemicals in man. Third Ed. Year Book Medical Publishers, Inc. Chicago, London, Boca Raton, Littleton MA.

Dietzen DJ, Ecos K, Friedman D, Beason S. Positive predictive values of abused drug immunoassays on the Beckman Synchron in a veteran population. J Anal Toxicol 2001 Apr;25(3):174-8. Veterans Affairs Medical Center, Department of Pathology, University of Tennessee School of Medicine, Memphis 38104, USA. dennis@pathology.utmem.edu

Drug Abuse Warning Network - DAWN - Publications Drug Abuse Warning Network (DAWN) The Drug Abuse Warning Network (DAWN) is an ongoing drug abuse data collection system sponsored by SAMHSA's Office of Applied Studies. www.samhsa.gov/oas/dawn.htm, <http://www.samhsa.gov/oas/dawn.htm>

Durback LF, Scharman EJ, Brown BS. Emergency physicians perceptions of drug screens at their own hospitals. Vet Hum Toxicol 1998 Aug;40(4):234-7. West Virginia Poison Center, West Virginia University School of Pharmacy, Charleston, USA.

Fudin J, Levasseur DJ, Passik SD, Kirsh KL, Coleman J. Chronic pain management with opioids in patients with past or current substance abuse problems. Journal of Pharmacy Practice. 2003, 16;4:291-308.

Passik SD, Schreiber J, Kirsh KL, Portenoy RK. A chart review of the ordering and documentation of urine toxicology screens in a cancer center: do they influence patient management? J Pain Symptom Manage 2000 Jan;19(1):40-4. Oncology Symptom Control Research, Community Cancer Care Inc., Indianapolis, IN 46202, USA.

Spanbauer AC, Casseday S, Davoudzadeh D, Preston KL, Huestis MA. Detection of opiate use in a methadone maintenance treatment population with the CEDIA 6-acetylmorphine and CEDIA DAU opiate assays..IRP, NIDA, J Anal Toxicol 2001 Oct;25(7):515-9 NIH, Baltimore, Maryland 21224, USA.